Recent studies have demonstrated that post-infarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction [19] suggesting promising therapeutic potential of exogenous decorin for the treatment of acute myocardial infarction. This evidence concerns the gene DCN and myocardial infarction.